drugset / Trial / NCT02046213

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

NCT02046213

Phase 1 Completed 16 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the metabolism and excretion of \[14C\]E2006 in healthy male subjects.

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 10 mg Oral

Indications

No indication recorded.